|
|
MyD88/CD40 |
|
Vaxjo ID |
321 |
|
Vaccine Adjuvant Name |
MyD88/CD40 |
|
Adjuvant VO ID |
VO_0005659
|
|
Description |
A chimeric adjuvant that combines innate and adaptive immune signaling. |
|
Stage of Development |
Research |
|
Components |
encoded chimeric MyD88/CD40 (MC) adjuvant |
|
Structure |
Chimeric MyD88/CD40 |
|
Function |
To be optimally effective, immunological adjuvants are required for the activation of tumor-specific CD8+ T cells responses by DNA vaccination. Here, we describe enhanced anti-tumor efficacy of an in vivo electroporation-delivered DNA vaccine by inclusion of a genetically encoded chimeric MyD88/CD40 (MC) adjuvant, which integrates both innate and adaptive immune signaling pathways |
| References |
Collinson-Pautz et al., 2016: Collinson-Pautz MR, Slawin KM, Levitt JM, Spencer DM. MyD88/CD40 Genetic Adjuvant Function in Cutaneous Atypical Antigen-Presenting Cells Contributes to DNA Vaccine Immunogenicity. PloS one. 2016; 11(10); e0164547. [PubMed: 27741278].
|
|
